Right Drug, Right Dose, Right Patient: Pharmacogenomics Tools Every Sleep Clinician Should Know in 2026

Why does one patient sleep soundly on a low dose of a medication while another is groggy until noon on the same prescription — or gets no benefit at all? Increasingly, part of the answer is in the genes that govern how we metabolize these drugs. Dr. Vishal Saini surveys the pharmacogenomics tools now available to sleep clinicians — the guidelines, the databases, the gene-drug pairs that actually matter in sleep medicine — and gives an honest appraisal of where testing helps and where it's still oversold.

By Dr. Vishal Saini, M.D., FAASM — Research & Medical Director, Mid-West Center for Sleep Disorders

Pharmacogenomics — tailoring drug choice and dose to a patient's genetic makeup — has quietly become one of the most practical ways that genetics enters everyday medicine. Unlike the polygenic risk scores that dominate headlines but rarely change what we do for an individual, pharmacogenomics is built on a handful of well-characterized genes with large, interpretable effects. As two leaders in the field put it, inherited variation in roughly 20 genes is now actionable in the clinic and affects about 80 medications (Relling & Evans, Nature, 2015, PMID 26469045) — and a striking share of those medications are ones we use in sleep medicine or borrow from our psychiatric and neurologic colleagues.

Sleep clinicians don't always think of ourselves as pharmacogenomics prescribers, but we should. We prescribe sedating antidepressants, hypnotics, benzodiazepines, wake-promoting agents, and anticataplectics — many of which are metabolized by the very enzymes pharmacogenomic testing characterizes. This article is a practical map of the tools now available, the gene-drug pairs that genuinely matter for our patients, and how to use them without overpromising.

The Core Tools: Where the Trustworthy Guidance Lives

The single most important thing to understand is that pharmacogenomics in 2026 is no longer a Wild West of proprietary algorithms. There is a mature, free, peer-reviewed infrastructure that tells you what a given genotype means and what to do about it. Four resources anchor responsible practice:

CPIC (the Clinical Pharmacogenetics Implementation Consortium). This is the one to know. CPIC publishes rigorous, regularly updated, peer-reviewed guidelines that translate a specific genotype into a specific prescribing action — not "this patient has a variant," but "this patient is a CYP2D6 poor metabolizer, so reduce the dose or choose an alternative." CPIC guidelines exist for exactly the drug classes we use, including detailed dosing guidance for antidepressants based on CYP2D6 and CYP2C19 genotype (Hicks et al., Clinical Pharmacology & Therapeutics, 2015, PMID 25974703; and for tricyclics, Hicks et al., 2017, PMID 27997040).

PharmGKB. The knowledge base that curates the underlying evidence — gene-drug annotations, variant effects, and links to every CPIC guideline. It's the reference library behind the recommendations.

FDA pharmacogenomic labeling. The FDA maintains a Table of Pharmacogenomic Biomarkers in Drug Labeling, and many drugs now carry genetic information in their official prescribing information. Usefully, one recent analysis mapped where FDA labeling and CPIC evidence levels agree and diverge — a reminder that a biomarker mentioned on a label isn't always backed by the same strength of actionable evidence as a CPIC guideline (Deb et al., Medicines, 2024, PMID 38535119).

Standardized genotype-to-phenotype translation. A practical headache in this field has been that the same genotype could be called "intermediate" by one lab and "poor metabolizer" by another. CPIC and the Dutch Pharmacogenetics Working Group have published consensus standards — most notably for CYP2D6 — so that a result means the same thing wherever it's run (Caudle et al., Clinical and Translational Science, 2020, PMID 31647186).

Together these turn a raw genotype into an actionable clinical instruction. If you take nothing else from this piece: when a pharmacogenomic result lands on your desk, check it against CPIC before acting.

"The value of pharmacogenomics isn't the genotype — it's the translation. A variant means nothing until a resource like CPIC tells you precisely what to do differently at the point of prescribing. That's what separates modern pharmacogenomics from the gene-report novelty of a decade ago." — Dr. Vishal Saini

The Gene-Drug Pairs That Actually Matter in Sleep Medicine

So where does this touch the drugs we actually prescribe? Several places, and they're worth knowing specifically.

The antidepressants we use for sleep. This is the richest vein. Doxepin — a tricyclic — is FDA-approved at low dose specifically for sleep-maintenance insomnia, and trazodone and mirtazapine are among the most commonly prescribed off-label hypnotics in the country. The tricyclics are directly covered by a CPIC guideline keyed to CYP2D6 and CYP2C19 genotype (Hicks et al., 2017, PMID 27997040), and the SSRIs and SNRIs we use for the anxiety and depression that so often drive insomnia are covered as well (Hicks et al., 2015, PMID 25974703). A CYP2D6 poor metabolizer may accumulate higher levels of a tricyclic and be more prone to anticholinergic and cardiac effects; an ultrarapid metabolizer may get too little. For the patient who is inexplicably sensitive to, or unresponsive to, these agents, genotype can be genuinely explanatory.

Benzodiazepines and the "Z-drugs." Several benzodiazepines (notably diazepam and clobazam) are CYP2C19 substrates, and poor metabolizers can experience prolonged sedation; pharmacogenetic variability in anxiolytic metabolism is well described (Radosavljevic et al., Genes, 2023, PMID 37239455). The non-benzodiazepine hypnotics lean heavily on CYP3A4 — zolpidem, eszopiclone, and zaleplon are all substantially CYP3A-metabolized — which is why their most important "personalization" is often less about inherited genotype and more about CYP3A drug interactions and clearance differences (the same pharmacology behind the FDA's lower recommended zolpidem dose in women, who clear it more slowly).

The dual orexin receptor antagonists (DORAs). Suvorexant, lemborexant, and daridorexant — our newest and architecturally gentlest insomnia drugs — are CYP3A4 substrates. Here the actionable lesson is interaction-driven dosing: strong CYP3A inhibitors sharply raise exposure and require dose reduction or avoidance. It's a reminder that "pharmacogenomics" in the broad sense includes the phenotype your patient's other medications impose on these same enzymes.

Pitolisant — a sleep-specific pharmacogenomic flag. For narcolepsy, pitolisant (a histamine H3 antagonist/inverse agonist) is a CYP2D6 substrate, and this is one of the clearest sleep-specific, label-level pharmacogenomic considerations we have: its prescribing information calls for dose adjustment in CYP2D6 poor metabolizers and with strong CYP2D6 inhibitors (Romigi et al., Drug Design, Development and Therapy, 2018, PMID 30214155; Thorpy, CNS Drugs, 2020, PMID 31953791). When you reach for pitolisant, CYP2D6 status is a legitimate thing to have in mind.

The oxybates (Xyrem, Xywav, Lumryz) — the instructive exception. This question comes up often, and the answer is genuinely useful to understand: there is no established, clinically actionable pharmacogenomic test for the oxybates, and the reason is pharmacologically elegant. Sodium oxybate (Xyrem), lower-sodium mixed-salt oxybate (Xywav), and extended-release sodium oxybate (Lumryz) are all formulations of gamma-hydroxybutyrate (GHB) — and GHB is not a cytochrome P450 substrate. It's metabolized instead by GHB dehydrogenase into the body's central energy machinery (ultimately the Krebs cycle, to carbon dioxide and water), with notably complex, nonlinear ("capacity-limited") absorption, metabolism, and renal handling, and transport by monocarboxylate transporters rather than the CYP enzymes (Felmlee et al., The AAPS Journal, 2021, PMID 33417072). Because the entire CYP-based pharmacogenomic toolkit — CPIC dosing guidelines, the metabolizer phenotypes, the commercial panels — is built around CYP enzymes, it simply doesn't map onto oxybate. A standard pharmacogenomic panel will tell you nothing actionable about how your patient will handle Xywav.

So how do we personalize oxybate? The old-fashioned way, and appropriately so: careful clinical titration to response and tolerability, weight-based dosing in children and adolescents (its clearance is nonlinear and tracks better with body weight than with absolute dose) (Chen et al., Clinical and Translational Science, 2020, PMID 32216084), and vigilant attention to its genuinely important — and entirely non-genetic — safety issues: its profound interaction with alcohol and other CNS depressants, and the sodium load that drove the development of the lower-sodium Xywav formulation. There is intriguing early research into whether transporter genes (for example the P-glycoprotein gene ABCB1, studied in relation to modafinil and venlafaxine response in narcolepsy) might one day help predict treatment response (Moresco et al., Clinical Neuropharmacology, 2016, PMID 26757307), but this is investigational, not yet oxybate-specific, and nowhere near the clinic. For now, the honest message to a patient asking whether a gene test can optimize their Xyrem or Xywav is: not yet — and here's why your careful dose titration is doing exactly the right job instead.

Caffeine, for completeness. The most-consumed wake-promoting drug in the world is metabolized by CYP1A2, and common variants make some people fast and others slow caffeine metabolizers — the slow metabolizers being those for whom an afternoon coffee genuinely does wreck the night. It's rarely a formal test, but it's a useful concept when counseling patients on caffeine timing.

A note on HLA and hypersensitivity. Distinct from metabolism, certain HLA alleles predict serious drug hypersensitivity reactions — relevant when sleep clinicians reach for anticonvulsants (for example in some movement or parasomnia contexts), where HLA typing before carbamazepine is an established safety practice. It's a different branch of pharmacogenomics — safety rather than dosing — but worth keeping on the radar.

The Honest Part: What Panel Testing Can and Can't Promise

Here's where I want to be candid, because this is where the marketing runs ahead of the evidence.

The tools above describe single, well-validated gene-drug pairs. Separately, a thriving commercial industry sells multi-gene "combinatorial" panels — particularly for psychiatry — that test many genes at once and return a proprietary, often color-coded "use / use with caution / avoid" report. These are heavily marketed, including directly to patients, and they're seductive. The honest reading of the evidence is that they are promising but not definitive. The largest randomized trial of combinatorial testing to guide antidepressant selection, the GUIDED trial, did not meet its primary endpoint of symptom improvement, though it did show modest benefits on secondary measures like response and remission rates (Thase et al., Journal of Clinical Psychiatry, 2019, PMID 31721487). That's a real but limited signal — enough to take seriously, not enough to justify ordering a panel reflexively for every patient or treating its proprietary verdict as gospel over a CPIC-level single-gene result.

The field itself is clear-eyed that much of the heritable variation in drug response remains unexplained, and that implementation — getting the right result to the right clinician at the right moment — is now the central challenge, not discovery (Lauschke & Ingelman-Sundberg, Pharmacology Reviews, 2026, PMID 41806469). In other words, the science is real and maturing, but it is an adjunct to good clinical judgment, not a substitute for it.

"I treat a pharmacogenomic panel the way I treat any consultant's report: valuable input, not a verdict. When it aligns with a CPIC guideline for a specific gene and drug, I lean on it. When it offers a proprietary composite score with no transparent evidence trail, I weigh it against what I can actually verify — and against how the patient in front of me is doing." — Dr. Vishal Saini

How to Actually Use These Tools in Practice

Pulling it together, here's the practical framework I'd offer a sleep clinician.

Reach for genotyping reactively when a patient's response doesn't make sense. The patient who is knocked out for twelve hours by a standard hypnotic dose, who gets no effect from an antidepressant at a normal dose, or who has intolerable side effects that don't fit — these are the patients in whom a CYP2D6/CYP2C19 result can be genuinely explanatory and change the next prescription.

Use it preemptively in higher-stakes prescribing. When starting a tricyclic like doxepin, an SSRI/SNRI for comorbid mood or anxiety, or pitolisant for narcolepsy, knowing metabolizer status in advance can help you start at the right dose rather than discovering the problem through a bad reaction.

Always route the result through CPIC (and PharmGKB). Don't act on a raw "variant detected" line or a proprietary color alone. Confirm the genotype-to-phenotype call and the specific dosing recommendation against the free, peer-reviewed guideline.

Remember that phenotype isn't only inherited. Your patient's other medications — strong CYP3A or CYP2D6 inhibitors and inducers — can convert a genetically "normal" metabolizer into a functional poor or ultrarapid one. Interaction checking is pharmacogenomics in practice.

Keep panels in perspective. A combinatorial panel can be a reasonable adjunct in the right complex patient, but interpret it with humility, prioritize transparent single-gene guidance, and never let a report override how your patient is actually responding.

A Practical Note: How to Order Pharmacogenomic Testing

Clinicians often ask which panel to order. The short answer is that you rarely build one yourself — nearly every clinical pharmacokinetic (PGx) panel already bundles the relevant genes — so the task is choosing a good panel and letting CPIC do the interpretation.

Genes to confirm are included: CYP2D6 and CYP2C19 are the must-haves (antidepressant hypnotics, pitolisant); CYP3A4/CYP3A5 cover the Z-drugs and DORAs; CYP1A2, CYP2B6, and CYP2C9 round out a comprehensive panel. A standard "comprehensive PK panel" contains all of these, so this is one test, not an à-la-carte build.
The spec that matters most: make sure the assay calls CYP2D6 with copy-number/structural-variant detection. CYP2D6 has gene deletions and duplications, and a SNP-only panel will silently misclassify the poor and ultrarapid metabolizers you are testing for.
Favor transparent, guideline-based reports: CLIA/CAP-accredited labs that return star-allele genotypes and CPIC/DPWG phenotype calls, rather than a proprietary color score with no evidence trail (the black-box combinatorial panels carry the weaker, GUIDED-trial-level evidence). Comprehensive PGx panels and single-gene CYP2D6/CYP2C19 tests are available through major reference labs.
Reactive vs. preemptive: for a single targeted question (e.g., CYP2D6 status before doxepin or pitolisant), order a single-gene test — cheaper and faster. If you expect to prescribe across these classes over time, a one-time comprehensive panel is more efficient, since genotype is lifelong: order once, reference forever.
Two caveats: the DORAs and Z-drugs are largely a drug–drug interaction story (CYP3A inhibitors/inducers causing phenoconversion) that a genotype panel will not capture, so interaction checking remains essential; and interpretation is free — run the star alleles through CPIC and PharmGKB rather than trusting a vendor's composite verdict.

The Bottom Line

Pharmacogenomics is the part of genetics that most directly changes what a sleep clinician does on a given afternoon — not by diagnosing the disorder, but by helping get the drug and the dose right the first time. The tools to do this responsibly now exist and are free: CPIC guidelines for the actionable gene-drug pairs, PharmGKB for the evidence, FDA labeling for the regulatory view, and standardized genotype-to-phenotype translation so a result means the same thing everywhere. For sleep medicine specifically, the highest-yield pairs involve the antidepressants we use as hypnotics (CYP2D6/CYP2C19), the benzodiazepines and Z-drugs (CYP2C19/CYP3A), the DORAs (CYP3A interactions), and pitolisant (CYP2D6). Multi-gene commercial panels are promising but still an adjunct, not an oracle. Used thoughtfully — reactively when a response puzzles you, preemptively in higher-stakes prescribing, and always filtered through validated guidelines — pharmacogenomics is one of the most practical precision-medicine tools we have. The genotype is only the beginning; the translation is where the medicine happens.

Dr. Vishal Saini, M.D., FAASM is the Research & Medical Director at Mid-West Center for Sleep Disorders, which operates its own sleep laboratories and manages the full range of sleep disorders — insomnia, narcolepsy, the hypersomnias, sleep apnea, and complex cases — with an emphasis on individualized, evidence-based pharmacotherapy, in Lansing, Traverse City, and Eaton Rapids.

Struggling to find a sleep medication that works for you without unacceptable side effects? Let's build a plan tailored to how your body actually handles these drugs.

Book a Consultation → | (517) 887-6733

References: Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature 2015;526(7573):343–350 (PMID 26469045). Hicks JK, Bishop JR, Sangkuhl K, et al. CPIC Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther 2015;98(2):127–134 (PMID 25974703). Hicks JK, Sangkuhl K, Swen JJ, et al. CPIC Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update. Clin Pharmacol Ther 2017;102(1):37–44 (PMID 27997040). Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from CPIC and the Dutch Pharmacogenetics Working Group. Clin Transl Sci 2020;13(1):116–124 (PMID 31647186). Deb S, Hopefl R, Reeves AA, Cvetkovic D. ADME Gene-Related Pharmacogenomic Labeling of FDA-Approved Drugs: Comparison with CPIC Evidence Levels. Medicines (Basel) 2024;11(3):6 (PMID 38535119). Radosavljevic M, Svob Strac D, Jancic J, Samardzic J. The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy. Genes (Basel) 2023;14(5):1095 (PMID 37239455). Romigi A, Vitrani G, Lo Giudice T, et al. Profile of pitolisant in the management of narcolepsy. Drug Des Devel Ther 2018;12:2665–2675 (PMID 30214155). Thorpy MJ. Recently Approved and Upcoming Treatments for Narcolepsy. CNS Drugs 2020;34(1):9–27 (PMID 31953791). Thase ME, Parikh SV, Rothschild AJ, et al. Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial (GUIDED). J Clin Psychiatry 2019;80(6):19m12910 (PMID 31721487). Lauschke VM, Ingelman-Sundberg M. The evolving landscape of pharmacogenomics: Current achievements and future directions. Pharmacol Rev 2026;78(2):100122 (PMID 41806469). Felmlee MA, Morse BL, Morris ME. γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology. AAPS J 2021;23(1):22 (PMID 33417072). Chen C, Rosen CL, Ruoff C, et al. Population and Noncompartmental Pharmacokinetics of Sodium Oxybate Support Weight-Based Dosing in Children and Adolescents With Narcolepsy With Cataplexy. Clin Transl Sci 2020;13(5):932–940 (PMID 32216084). Moresco M, Riccardi LN, Pizza F, et al. Pharmacogenetics and Treatment Response in Narcolepsy Type 1: Relevance of the Polymorphisms of the Drug Transporter Gene ABCB1. Clin Neuropharmacol 2016;39(1):18–23 (PMID 26757307).